Prioritizing treatment burden important for patients with cystic fibrosis

Findings published in Chest highlighted the importance of routinely capturing treatment burden among individuals with cystic fibrosis in clinical trials.
“The recent introduction of CFTR modulator therapies is transforming the outcomes and prognosis for many people with cystic fibrosis, with evidence emerging that their introduction is associated with reduced use of other treatments,” Rory A. Cameron, PhD, MScPH, research scientist at Norwich Medical School at the University of East Anglia, England, and colleagues wrote. “To date, however, these innovations have been designed

Findings published in Chest highlighted the importance of routinely capturing treatment burden among individuals with cystic fibrosis in clinical trials.
“The recent introduction of CFTR modulator therapies is transforming the outcomes and prognosis for many people with cystic fibrosis, with evidence emerging that their introduction is associated with reduced use of other treatments,” Rory A. Cameron, PhD, MScPH, research scientist at Norwich Medical School at the University of East Anglia, England, and colleagues wrote. “To date, however, these innovations have been designed